静脉注射解决方案市场- 按类型（总、外周肠外营养）、成分（碳水化合物、维生素和矿物质、单剂量氨基酸、肠外脂质乳剂）、年龄组、应用、最终用户、全球预测，2024 - 2032 年

在持续研究和开发的推动下，2024 年至 2032 年间，全球静脉解决方案市场份额的复合年增长率将达到 7.5%。随着医学科学的进步，将液体、电解质和药物直接有效输送到血液中的需求变得越来越重要。

例如，2023 年 11 月，最近的一项荟萃分析显示，使用静脉输液 (IV) 治疗的平衡溶液而不是常用的生理食盐水，可以将重症患者的院内死亡风险降低 4%。 BEST-Living 研究的结果在加拿大重症监护论坛 (CCCF 2023) 上发表，并同时发表在《柳叶刀呼吸医学》杂誌上，其结果表明对患者治疗结果有重大影响。着名重症监护医师、乔治全球健康研究所教授研究员 Simon Finfer AO 教授强调了重症监护治疗中静脉输液选择的重要性。

药物配方和医疗技术的不断创新推动了针对特定患者需求的新型静脉注射解决方案的发展。随着人们专注于改善患者治疗效果和加强医疗保健服务，对静脉注射解决方案的需求持续增长，反映了医疗保健行业的动态特性。

静脉注射解决方案行业的整体规模根据类型、组成、年龄层、应用、最终用户和地区进行分类。

2024年至2032年，週边肠外营养领域将经历重大发展。专为 PPN 量身定制的静脉解决方案将必需的营养素直接输送到血液中，解决营养不良问题并支持患者康復。随着医疗保健提供者认识到 PPN 在各种临床环境中的优势，对专业静脉注射解决方案的需求持续增长，推动了市场扩张。

从2024 年到2032 年，维生素和矿物质领域的静脉注射解决方案市场份额将实现显着的复合年增长率。吸收不良问题或无法食用口服补充剂的患者。随着医疗保健提供者优先考虑患者的最佳营养和健康，对富含维生素和矿物质的静脉注射解决方案的需求持续增长，反映了医疗保健环境中全面营养支持的重要性。

MEA 静脉注射解决方案市场从2024 年到2032 年将呈现出值得称讚的复合年增长率。的需求不断成长。该地区的医疗保健部门强调静脉注射治疗对患者管理和治疗的重要性。随着政府和医疗保健提供者优先考虑改善医疗保健服务和质量，MEA 地区对静脉注射解决方案的需求持续增长，推动市场成长。

例如，2023 年 11 月，为了支持苏丹的医疗保健产业，卡达慈善机构透过提供静脉注射解决方案提供了支持。该组织最近向半岛电视台和盖达里夫州的卫生和人道主义机构运送了这些重要的医疗用品。其目的是协助该地区应对登革热和腹泻等流行的健康挑战。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 营养不良病例不断增加
    • 早产率高
    • 胃肠道疾病、神经系统疾病和癌症等疾病的盛行率不断增加
    • 外科手术数量不断增加
  • 产业陷阱与挑战
    • 严格的监管和品质要求
• 成长潜力分析
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按类型，2018 - 2032

• 主要趋势
• 全肠外营养
• 週边肠外营养

第 6 章：市场估计与预测：按构成，2018 年 - 2032 年

• 主要趋势
• 碳水化合物
• 维生素和矿物质
• 单剂量胺基酸
• 肠外脂肪乳剂
• 其他作品

第 7 章：市场估计与预测：按年龄划分，2018 - 2032

• 主要趋势
• 儿科
• 成人
• 老年科

第 8 章：市场估计与预测：按应用分类，2018 - 2032

• 主要趋势
• 营养支持
• 输血
• 液体和电解质平衡
• 其他应用

第 9 章：市场估计与预测：按最终用户划分，2018 年 - 2032 年

• 主要趋势
• 医院和诊所
• 门诊手术中心
• 家庭护理设置

第 10 章：市场估计与预测：按地区，2018 - 2032

• 主要动向：按地区
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 中东和非洲其他地区

第 11 章：公司简介

• Ajinomoto Co., Inc.
• Amanta Healthcare
• Axa Parenterals Ltd
• B. Braun Melsungen AG
• Baxter International Inc.
• Fresenius Kabi USA, LLC
• Grifols, S.A.
• ICU Medical. Inc
• JW Life Science
• Otsuka Pharmaceutical Co., Ltd
• Pfizer, Inc.

Global Intravenous Solutions Market share will witness 7.5% CAGR between 2024 and 2032, propelled by ongoing research and developments. As medical science advances, the need for effective delivery of fluids, electrolytes, and medications directly into the bloodstream becomes increasingly crucial.

For instance, in November 2023, A recent meta-analysis revealed that using balanced solutions of intravenous fluid (IV) therapy, rather than the commonly used saline, may reduce the risk of in-hospital death among critically ill patients by 4%. Presented at the Critical Care Canada Forum (CCCF 2023) and concurrently published in The Lancet Respiratory Medicine, the findings from the BEST-Living Study indicate a significant impact on patient outcomes. Professor Simon Finfer AO, a renowned Intensive Care physician and Professorial Fellow at The George Institute for Global Health, emphasized the importance of IV fluid selection in intensive care treatment.

Continuous innovations in pharmaceutical formulations and medical technology drive the development of new intravenous solutions tailored to specific patient needs. With a focus on improving patient outcomes and enhancing healthcare delivery, the demand for intravenous solutions continues to grow, reflecting the dynamic nature of the healthcare industry.

The overall Intravenous Solutions Industry size is classified based on the type, composition, age group, application, end-user, and region.

The peripheral parental nutrition segment will undergo significant development from 2024 to 2032. PPN plays a vital role in providing essential nutrients to patients who can not consume adequate nutrition orally. Intravenous solutions tailored for PPN deliver essential nutrients directly into the bloodstream, addressing malnutrition and supporting patient recovery. As healthcare providers recognize the benefits of PPN in various clinical settings, the demand for specialized intravenous solutions continues to grow, driving market expansion.

The intravenous solutions market share from the vitamins and minerals segment will register a noteworthy CAGR from 2024 to 2032. These solutions play a critical role in delivering essential nutrients directly into the bloodstream, particularly for patients with malabsorption issues or those unable to consume oral supplements. As healthcare providers prioritize optimal patient nutrition and wellness, the demand for intravenous solutions enriched with vitamins and minerals continues to grow, reflecting the importance of comprehensive nutritional support in healthcare settings.

MEA intravenous solutions market will showcase a commendable CAGR from 2024 to 2032. With expanding healthcare infrastructure and the rising prevalence of chronic diseases, there's a growing need for intravenous solutions to deliver vital fluids, electrolytes, and medications. The region's healthcare sector is emphasizing the importance of intravenous therapy for patient management and treatment. As governments and healthcare providers prioritize improving healthcare access and quality, the demand for intravenous solutions in the MEA region continues to rise, driving market growth.

For instance, in November 2023, in an ongoing effort to bolster Sudan's healthcare sector, Qatar Charity extended support by supplying intravenous solutions. The organization recently dispatched shipments of these vital medical supplies to health and humanitarian agencies in Al-Jazeera and Gedaref states. The aim is to assist in combating prevalent health challenges like dengue fever and diarrhea in the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing cases of malnutrition
    • 3.2.1.2 High prevalence of pre-term births
    • 3.2.1.3 Increasing prevalence of diseases, such as gastrointestinal disorder, neurological diseases, and cancer
    • 3.2.1.4 Increasing number of surgical procedures
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory and quality requirements
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
  • 3.5.1 Supplier power
  • 3.5.2 Buyer power
  • 3.5.3 Threat of new entrants
  • 3.5.4 Threat of substitutes
  • 3.5.5 Industry rivalry
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Total parenteral nutrition
• 5.3 Peripheral parenteral nutrition

Chapter 6 Market Estimates and Forecast, By Composition, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Carbohydrates
• 6.3 Vitamins & minerals
• 6.4 Single-dose amino acids
• 6.5 Parenteral lipid emulsion
• 6.6 Other compositions

Chapter 7 Market Estimates and Forecast, By Age Group, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Pediatric
• 7.3 Adult
• 7.4 Geriatric

Chapter 8 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Nutritional support
• 8.3 Blood transfusion
• 8.4 Fluid & electrolyte balance
• 8.5 Other applications

Chapter 9 Market Estimates and Forecast, By End-User, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals and clinics
• 9.3 Ambulatory surgery centers
• 9.4 Home care settings

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 10.1 Key trends, by region
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Ajinomoto Co., Inc.
• 11.2 Amanta Healthcare
• 11.3 Axa Parenterals Ltd
• 11.4 B. Braun Melsungen AG
• 11.5 Baxter International Inc.
• 11.6 Fresenius Kabi USA, LLC
• 11.7 Grifols, S.A.
• 11.8 ICU Medical. Inc
• 11.9 JW Life Science
• 11.10 Otsuka Pharmaceutical Co., Ltd
• 11.11 Pfizer, Inc.